Vivus' Qsymia set to be most widely used emerging therapy for obesity treatment
Novel emerging agents will experience rapid uptake owing to the high prevalence of obese or overweight individuals and the current lack of efficacious, safe and well-tolerated weight-loss drugs, notes a new report from advisory firm Decision Resources.
Among the new agents to enter the market, Vivus’ (Nasdaq: VVUA) Qsymia (phentermine and topiramate extended-release) will become the most widely used emerging therapy due to efficacy superior to its competitors. Qsymia, approved by the US Food and Drug Administration this month (The Pharma Letter July 18), is scheduled to launch in 2012 and will help to fulfill the need for more efficacious agents, providing greater than double the weight-loss efficacy of currently available drugs including Roche’s Xenical (orlistat, phentermine (UCB’s Ionamin, generics) and GlaxoSmithKline’s over-the-counter product Alli (orlistat).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze